Pyrrolopyridine Inducers for Chemical Oct4 Activation and MET
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing mesenchymal-to-epithelial transition (MET) in cellular reprogramming are inefficient and often rely on viral or vector-based modulation of the Oct4 protein, which can be risky and complex.
Innovation Solution
Development of pyrrolopyridine derivatives that bind to the Oct4 protein and regulatory microRNAs, chemically activating Oct4 to regulate downstream gene expression and induce MET in various cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral or vector-based modulation of Oct4 protein is used to induce MET, then the reprogramming process can be achieved, but the method becomes risky and complex
Solution Approach 1:
The patent replaces viral or vector-based modulation methods with small molecule chemical compounds that bind to and activate Oct4 protein. This substitution eliminates the complexity and safety risks associated with viral vectors while achieving the same reprogramming outcome through a simpler chemical mechanism.
Solution Approach 2:
The patent uses small molecule compounds that change the functional state of Oct4 protein through binding interactions. These compounds modulate the protein's activity parameters without requiring genetic modification or viral delivery, thereby simplifying the overall system while maintaining reprogramming effectiveness.
2Reliability
If viral or vector-based modulation is used to induce MET, then reprogramming can be achieved, but the process becomes risky
Solution Approach 1:
The patent substitutes viral-based systems with small molecule pharmacological agents that directly activate Oct4. This replacement maintains reprogramming efficiency while significantly improving safety by eliminating viral integration risks and immunogenicity concerns.
Solution Approach 2:
The patent employs small molecule compounds that can be easily administered and metabolized, replacing persistent viral vectors. These small molecules provide temporary, controllable activation of Oct4 without leaving long-term genetic modifications, thereby improving safety while maintaining functional effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a safer and simpler approach to enhance biological expression and induce MET, avoiding the need for viral modulation, and effectively promoting cellular reprogramming.
Implementation Method 1
pyrrolopyridine derivatives capable of simultaneously binding to both the Oct4 protein and the regulatory miRNAs
Implementation Method 2
The pyrrolopyridine derivatives are capable of chemically activating Oct4, hereby regulating the expression of its downstream genes
Implementation Method 3
inducing the expression of epithelial-associated genes and early reprogramming genes
Implementation Method 4
inducing the conversion of mesenchymal cells into epithelial cells
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a pyrrolopyridine derivative and its application. The pyrrolopyridine derivative is a compound capable of inducing the conversion of mesenchymal cells into epithelial cells, and has the following structure: wherein m1, m2, A2, and A3 are as described herein.